Special Issue

The Application of Pharmacogenetics in Toxicity Prevention and Drug Effect Improvement

Message from the Guest Editor

Pharmacogenomics, the study of how an individual's genetic makeup influences their response to drugs, has increasingly gained prominence in personalized medicine. Recent developments include the identification of new genetic markers associated with drug metabolism, efficacy, and adverse reactions. The integration of next-generation sequencing technologies has allowed for more comprehensive genomic profiling, enabling healthcare professionals to tailor drug prescriptions based on an individual's genetic profile. The ongoing progress in pharmacogenomics holds promise for optimizing drug therapy, minimizing adverse effects, and improving overall patient outcomes. This Special Issue aims to gather cutting-edge research, innovative methodologies, and insightful perspectives that contribute to the understanding and advancement of pharmacogenetics, strategies for preventing drug toxicity, and methods for enhancing drug efficacy. We believe that your expertise in "Pharmacogenetics" would significantly enrich the content of this Special Issue.

Guest Editor

Dr. Pura Ballester

Faculty of Pharmacy and Nutrition, Universidad Católica de Murcia (UCAM), campus los Jerónimos 177, Murcia, Spain

Deadline for manuscript submissions

closed (31 July 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/197405

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

